Literature DB >> 28983876

Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers.

I Castro-Ferreira1,2, Rute Carmo3, Sérgio Estrela Silva4,5, Otília Corrêa6, Susana Fernandes7,8, Susana Sampaio3,7, Rodrigues-Pereira Pedro9,10, Augusta Praça3,11, João Paulo Oliveira7,11,12.   

Abstract

Familial lecithin-cholesterol acyltransferase deficiency (FLD) is a rare recessive disorder of cholesterol metabolism, caused by loss-of-function mutations in the human LCAT gene, leading to alterations in the lipid/lipoprotein profile, with extremely low HDL levels.The classical FLD phenotype is characterized by diffuse corneal opacification, haemolytic anaemia and proteinuric chronic kidney disease (CKD); an incomplete form, only affecting the corneas, has been reported in a few families worldwide.We describe an intermediate phenotype of LCAT deficiency, with CKD preceding the development of corneal clouding, in two Portuguese brothers apparently homozygous for a novel missense LCAT gene mutation. The atypical phenotype, the diagnosis of membranous nephropathy in the proband's native kidney biopsy, the late-onset and delayed recognition of the corneal opacification, the co-segregation with Gilbert syndrome and the late recurrence of the primary disease in kidney allograft all contributed to obscure the diagnosis of an LCAT deficiency syndrome for many years.A major teaching point is that on standard light microscopy examination the kidney biopsies of patients with LCAT deficiency with residual enzyme activity may not show significant vacuolization and may be misdiagnosed as membranous nephropathy. The cases of these two patients also illustrate the importance of performing detailed physical examination in young adults presenting with proteinuric CKD, as the most important clue to the diagnosis of FLD is in the eyes.

Entities:  

Keywords:  Corneal clouding; Familial lecithin-cholesterol acyltransferase deficiency; Familial lecithin-cholesterol acyltransferase deficiency-associated nephropathy; Gilbert syndrome; Kidney transplantation

Year:  2017        PMID: 28983876      PMCID: PMC6122021          DOI: 10.1007/8904_2017_57

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  26 in total

1.  Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation.

Authors:  V Panescu; Y Grignon; D Hestin; G Rostoker; L Frimat; E Renoult; J Gamberoni; G Grignon; M Kessler
Journal:  Nephrol Dial Transplant       Date:  1997-11       Impact factor: 5.992

2.  Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.

Authors:  E G Lynn; Y L Siow; J Frohlich; G T Cheung; K O
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 3.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

Authors:  J A Kuivenhoven; H Pritchard; J Hill; J Frohlich; G Assmann; J Kastelein
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

4.  Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.

Authors:  Masato Nishiwaki; Katsunori Ikewaki; Giovanni Bader; Hassan Nazih; Minna Hannuksela; Alan T Remaley; Robert D Shamburek; H Bryan Brewer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-16       Impact factor: 8.311

5.  The genetic defect of the original Norwegian lecithin:cholesterol acyltransferase deficiency families.

Authors:  G Skretting; J P Blomhoff; J Solheim; H Prydz
Journal:  FEBS Lett       Date:  1992-09-14       Impact factor: 4.124

6.  Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans.

Authors:  Laura Calabresi; Damiano Baldassarre; Samuela Castelnuovo; Paola Conca; Letizia Bocchi; Chiara Candini; Beatrice Frigerio; Mauro Amato; Cesare R Sirtori; Paola Alessandrini; Marcello Arca; Giuliano Boscutti; Luigi Cattin; Loreto Gesualdo; Tiziana Sampietro; Gaetano Vaudo; Fabrizio Veglia; Sebastiano Calandra; Guido Franceschini
Journal:  Circulation       Date:  2009-08-18       Impact factor: 29.690

7.  Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency.

Authors:  Sara Simonelli; Cristina Tinti; Laura Salvini; Laura Tinti; Alice Ossoli; Cecilia Vitali; Vitor Sousa; Gaetano Orsini; Maria Luisa Nolli; Guido Franceschini; Laura Calabresi
Journal:  Biologicals       Date:  2013-10-18       Impact factor: 1.856

Review 8.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

9.  Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs).

Authors:  P Aranda; P Valdivielso; L Pisciotta; I Garcia; C Garcã A-Arias; S Bertolini; G Martã N-Reyes; S Calandra
Journal:  Clin Nephrol       Date:  2008-03       Impact factor: 0.975

10.  In vivo imaging of the cornea in a patient with lecithin-cholesterol acyltransferase deficiency.

Authors:  Pat-Michael Palmiero; Zaher Sbeity; Jeffrey Liebmann; Robert Ritch
Journal:  Cornea       Date:  2009-10       Impact factor: 2.651

View more
  4 in total

1.  Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol.

Authors:  Kelly A Manthei; Shyh-Ming Yang; Bolormaa Baljinnyam; Louise Chang; Alisa Glukhova; Wenmin Yuan; Lita A Freeman; David J Maloney; Anna Schwendeman; Alan T Remaley; Ajit Jadhav; John Jg Tesmer
Journal:  Elife       Date:  2018-11-27       Impact factor: 8.140

Review 2.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

3.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

4.  Gene Mutation Classification through Text Evidence Facilitating Cancer Tumour Detection.

Authors:  Meenu Gupta; Hao Wu; Simrann Arora; Akash Gupta; Gopal Chaudhary; Qiaozhi Hua
Journal:  J Healthc Eng       Date:  2021-07-27       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.